The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis. Ahead of its extended target action date of March 12, 2025, the FDA approved ...

Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative ...

"With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there is now a therapy that offers the potential for powerful skin clearance with no ...

1% for the treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older. An aryl hydrocarbon receptor agonist, tapinarof cream, 1% was first approved in May 2022 ...

for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older. The approval was based on data from 2 multicenter, randomized, double-blind, vehicle ...

Educational interventions for patients, including both in-person and online methods, significantly reduced atopic dermatitis (AD) severity.

2024 EADV 2024 Children With Severe AD Catch Up on Growth With Dupilumab Effective treatment with dupilumab may allow younger children with severe atopic dermatitis and short stature to catch up ...